




Pharmacy and Therapeutics Committee Approvals, August 2008

P&T Date: August 5, 2008

AGENDA ITEM	P&T COMMITTEE DECISION	COMMENTS
<ul style="list-style-type: none"> NICARDIPINE FOR INJECTION (CARDENE® IV) 	<p style="text-align: center;">RETAIN NON-FORMULARY STATUS BUT ALLOW RESTRICTED USE IN A 6-MONTH TEST-OF-CHANGE IN HYPERTENSION MANAGEMENT OF (1) ACUTE ISCHEMIC STROKE IN PATIENTS RECEIVING RTPA AND (2) INTRACRANIAL HEMORRHAGE (ICH) FOR UP TO 48 HOURS. CONTINUE TO ALLOW INTRA-ARTERIAL USE FOR CEREBRAL VASOSPASM IN INTERVENTIONAL NEURORADIOLOGY</p>	<ul style="list-style-type: none"> Indication: Short-term treatment of hypertension when oral therapy is considered undesirable or not feasible Mechanism of Action: Inhibition of cardiac and smooth muscle transmembrane calcium ion influx without alteration of serum calcium concentration. Greater selectivity for L-type calcium channels in vascular smooth muscle than cardiac myocytes results in potent coronary and cerebral vasodilatory activity Adverse effects: Most common: headache, hypotension, phlebitis at injection site, tachycardia, EKG abnormalities, nausea, vomiting, dizziness, sweating, polyuria, and renal dysfunction. Can cause severe hypotension and pulmonary edema Contraindications: Contraindicated in patients with known hypersensitivity to nicardipine or in those with advanced aortic stenosis Precautions: Use with caution in the setting of CAD, CHF, hypertrophic cardiomyopathy, pheochromocytoma, renal or hepatic dysfunction. Peripheral infusion site should be changed every 12 hours to decrease risk of injection site phlebitis. Substrate of CYP_{3A4} (major); inhibits CYP_{2C9} (strong), 2C19 (moderate), 2D6 (moderate), 3A4 (strong). Cyclosporine levels should be closely monitored during concurrent nicardipine. Pregnancy category C; use not recommended in nursing mothers
<ul style="list-style-type: none"> AUTOMATIC SUBSTITUTION: ADVAIR HFA® TO ADVAIR DISKUS® 	<p style="text-align: center;">Fluticasone/salmeterol HFA inhaler (Advair HFA®) TO Fluticasone/salmeterol diskus (Advair diskus®) at ½ the number of HFA puffs at the same frequency</p> <div style="text-align: center;">  Advair Diskus.HFA auto sub </div>	
<ul style="list-style-type: none"> NEUROSCIENCES 	<ul style="list-style-type: none"> Guidelines for the Management of Brain Hemorrhage - FYI <div style="text-align: center;">  Brain Hemorrhage management guideline </div> <ul style="list-style-type: none"> Acute Stroke Care Code Brain Pathway (revision) <div style="text-align: center;">  Acute Stroke Care Code Brain pathway / </div> <ul style="list-style-type: none"> Algorithms for Acute Stroke 	



Acute Stroke
algorithm 07 08



Acute Ischemic
Stroke Algorithm 07 0

- **Transient Ischemic Attack (TIA) Physician Guidelines**



TIA Physician
Guideline 07 08

- **Algorithm for TIA**



TIA Pathway -
algorithm 07 08

- **tPA (Alteplase®) Administration Order Form**



9200 tPA Order Set
07 08

- **tPA (Alteplase®) Administration Inclusion/Exclusion Criteria**



tPA Inclusion
Exclusion Checklist 92

- **Admission Orders Transient Ischemia Attack**



Acrobat Document

- **DVT Prophylaxis in Stroke Patients**



DVT ppx in stroke pts
07 08

- **REMOVED FROM FORMULARY (DUE TO DISCONTINUATIONS BY MANUFACTURERS)**

- **Cortisporin® Ophthalmic Suspension**













Cortisporin ophthalmic

- **Cortisporin® Otic Suspension**



Cortisporin otic
suspension

- **Edrophonium (Enlon®)**

	 Enlon - baxter letter
<ul style="list-style-type: none"> • 2008 ANTIFUNGAL TREATMENT RECOMMENDATIONS – (REVISIONS TRACKED) 	 2008 Antifungal tx guidelines 07 08
<ul style="list-style-type: none"> • ANTIBIOTIC DOSING PER PHARMACY PROTOCOL (REVISIONS TRACKED) 	 Abx dosing protocol 07 08
<ul style="list-style-type: none"> • VANCOMYCIN PER PHARMACY PROTOCOL (REVISIONS TRACKED) 	 Vanco protocol 07 08
<ul style="list-style-type: none"> • MEDICATION SAFETY COLLABORATIVE 	<ul style="list-style-type: none"> • 2009 Medication Safety Collaborative Goals and Objectives  2009 MSC goals obj 07 08 <ul style="list-style-type: none"> • NCC MERP Categorization of Medication Errors  NCC MERP definition algorithm 07 08
<ul style="list-style-type: none"> • FDA ALERTS 	<ul style="list-style-type: none"> • FDA News and Warnings: May – July 2008 Summary  B11a. Medwatch Alerts May - July 2008 <ul style="list-style-type: none"> • Fluoroquinolones – increased risk of tendonitis and tendon rupture  B6e. FQ BBW 07.08.pdf <ul style="list-style-type: none"> • Abacavir (Ziagen®) – fatal hypersensitivity reactions associated with HLA-B*5701  B11b. Abacavir fatal hypersensitivity FDA <ul style="list-style-type: none"> • Antipsychotics (conventional and atypical) – increased risk of mortality in elderly patients  B11c. Antipsychotics FDA 06.08.pdf

- **Becaplermin (Regranex®) – increased risk of cancer in patients with diabetes (black box warning)**



B11d. Becaplermin
BBW 06.08.pdf

- **TNF Blockers (Remicade®, Enbrel®, Humira®, Cimzia®) – increased risk of lymphoma and other cancers in children and young adults**



B11e. TNF blockers
FDA 06.08.pdf

Requests for full monographs or questions regarding this listing may be addressed to the Drug Information Center at **(310) 423-3784**

Angela Hirai Yang, PharmD
Hai Tran, PharmD
Rita Shane, PharmD, FASHP

*Pharmacy Program Coordinator
Clinical Coordinator
Director, Department of Pharmacy*